Marshall Wace North America’s Procept Biorobotics PRCT Stock Holding History

Marshall Wace North America’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1.14M	Buy	+29,839	New	+$1.15M	﹤0.01%	878

Other funds holding PRCT

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Marshall Wace North America's PRCT Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Procept Biorobotics (PRCT) in Q3 2021: 29,839 shares worth $1.14M. The stake represents ﹤0.01% of the portfolio and ranks #878 among its holdings.

58 funds tracked by Wall St. Rank hold PRCT as of Q3 2021.

Marshall Wace North America held 29,839 shares of Procept Biorobotics worth $1.14M as of Q3 2021.
Procept Biorobotics was a new Marshall Wace North America position in Q3 2021.
Procept Biorobotics made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #878 holding.
58 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.